$Lexaria Bioscience (LEXX.US)$ show me the cash!!
$Lexaria Bioscience (LEXX.US)$ at this sp we gonna be all shares target...
$Lexaria Bioscience (LEXX.US)$ each time wanna fly someone is stoping the trend...so frustrating...imho should be at +$3. but looks. im all wrong.
71843878
liked and commented on
$Lexaria Bioscience (LEXX.US)$ $2.8/3 could b before year ends?
1
1
71843878
reacted to
$Lexaria Bioscience (LEXX.US)$
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Thursday, 19th December at 9:05 am
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss
KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (NASDAQ: LEXX)(NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). Th...
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Thursday, 19th December at 9:05 am
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss
KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (NASDAQ: LEXX)(NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). Th...
1
$Lexaria Bioscience (LEXX.US)$ looks like someone w deep pockets is shorting our play....sad.
71843878
liked
$Lexaria Bioscience (LEXX.US)$
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
1
71843878
liked
$Lexaria Bioscience (LEXX.US)$
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Lexaria Bioscience provides a strategic update on the expanding therapeutic benefits of GLP-1 drugs, highlighting their growing applications beyond diabetes and weight loss. The market, dominated by semaglutide and tirzepatide, has seen remarkable growth from $300 million in 2018 to projected $30 billion in 2024. New therapeutic applications being investigated include he...
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Lexaria Bioscience provides a strategic update on the expanding therapeutic benefits of GLP-1 drugs, highlighting their growing applications beyond diabetes and weight loss. The market, dominated by semaglutide and tirzepatide, has seen remarkable growth from $300 million in 2018 to projected $30 billion in 2024. New therapeutic applications being investigated include he...
1
71843878
liked
$Lexaria Bioscience (LEXX.US)$
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
Lexaria Bioscience Corp. (NASDAQ:LEXX) announces final 12-week results from its diabetes animal study WEIGHT-A24-1. All groups using DehydraTECH technology outperformed Rybelsus® in body weight control. DehydraTECH-liraglutide and DehydraTECH-CBD were top performers, surpassing Rybelsus® control group in body weight-loss b...
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
Lexaria Bioscience Corp. (NASDAQ:LEXX) announces final 12-week results from its diabetes animal study WEIGHT-A24-1. All groups using DehydraTECH technology outperformed Rybelsus® in body weight control. DehydraTECH-liraglutide and DehydraTECH-CBD were top performers, surpassing Rybelsus® control group in body weight-loss b...
1